Test drug for EGFR-mutant lung cancer without prior treatment
Treatments studied
Part of Cancer, Lungs & breathing clinical trials.
This Phase 3 trial studies TY-9591 in people with locally advanced or metastatic non-small cell lung cancer (NSCLC) that has specific EGFR gene changes. It’s for those who haven’t had earlier medicines for advanced lung cancer, and it aims to see if the drug works better or safer than the comparison treatment.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You’re 18 to 79 years old.
- Your lung cancer is NSCLC that has spread or is locally advanced, confirmed by lab testing.
- Your tumor has an EGFR “sensitive” mutation (like exon 19 deletion or L858R).
- You have not had chemotherapy, targeted therapy, immunotherapy, or other cancer medicines for advanced lung cancer before starting this study.
- You have at least one abnormal area the doctors can measure on scans for response tracking.
- Your heart, organ function (liver/kidney/bone marrow), and overall strength are good enough for study treatment.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This phase 2 trial studies TY-9591 in people with advanced non-small cell lung cancer (NSCLC) that has spread to the brain and has specific EGFR mutations. It aims to see whether the medicine can control the cancer in the brain and the rest of the body, without needing immediate brain radiation.
This trial tests a new targeted drug (TY-9591) combined with chemotherapy as a first treatment for people with advanced non-small cell lung cancer that has a specific EGFR mutation. It may offer a more effective option for those who haven't had prior therapy.
This trial tests a new drug called SYS6010 combined with osimertinib for people with advanced non-small cell lung cancer that has specific EGFR mutations. It aims to see if this combination works better than current treatments.
This trial collects data from people with early-stage lung cancer that has a common EGFR mutation. After complete surgical removal of the tumor, participants take osimertinib for 3 years and are followed regularly to see how well the treatment works and why resistance might develop.
This trial studies osimertinib in people with advanced or metastatic lung cancer that has specific EGFR gene changes. It aims to see how well this targeted medicine can control the cancer when surgery or radiotherapy won’t work.
This trial tests whether osimertinib alone is as good as osimertinib plus chemotherapy for lung cancers that have a specific EGFR mutation. It may help by improving how well the cancer responds and slows growth in people with metastatic non-small cell lung cancer.
Hear when a new EGFR Activating Mutation trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.